Bridging Regulatory & Commercial Expectations to Restructure the Pathway to Commercialization & Long-Term Follow Ups
- Evaluating long-term adverse event follow-up trends to determine clinically meaningful safety signals while reducing post-approval burden
- Interpreting evolving regulatory frameworks to enable adaptive decisions that balance patient safety, operational feasibility and commercial sustainability
- Aligning biotech, pharma, academia and patient advocacy stakeholders to support efficient commercialization strategies and evidence-driven long-term study design